NCT07513259Completed
Pre-Diagnosis GLP-1 Receptor Agonist Use and Post-Cancer Mortality in Adults With Obesity and Type 2 Diabetes
Pre-Diagnosis GLP-1 Receptor Agonist Use and Post-Cancer Mortality in Adults With Obesity and Type 2 Diabetes: A Target Trial Emulation
Source: ClinicalTrials.gov · Last updated 17 Aug 2026
Brief summary (registry, in English)
This study will examine whether the type of diabetes treatment used before cancer diagnosis is associated with survival and serious complications after obesity-associated cancer in adults with obesity and type 2 diabetes. The study focuses on glucagon-like peptide-1 receptor agonists (GLP-1 RA) and compares them with other commonly used glucose-lowering therapies, including SGLT2 inhibitors, DPP-4 inhibitors, sulfonylureas, metformin, and usual care. Using de-identified electronic health record data from the TriNetX US Collaborative Network, the study will assess whether patients who used GLP-1 RA before cancer diagnosis have different risks of death, hospitalization, sepsis, and other major outcomes after cancer diagnosis. This is an observational study designed to evaluate associations in routine clinical care and not to prove a treatment effect.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 203424 (actual)
- First submitted
- 31 Mar 2026
- Start date
- 1 Jan 2018
- Primary completion date
- 31 Oct 2025
- Lead sponsor
- Chung Shan Medical University
- Diseases
- Obesity, Type 2 diabetes
- NCT number
- NCT07513259
What you commit to
- Study type: Observational
- Participants enrolled: 203424
- From 1 Jan 2018 to the primary completion date, 31 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior bariatric surgery
- Prior organ transplantation
- Transplant-related complications
Other illness
- Type 1 diabetes mellitus, Other specified diabetes types that are not type 2 diabetes
- Human immunodeficiency virus infection
- End-stage renal disease
Other
- Any use of tirzepatide before cohort entry
Who the study is looking for
- Adults aged 18 years or older
- BMI ≥27 kg/m2, or diagnosis codes consistent with obesity
- Type 2 diabetes mellitus
- Initiation of a glucose-lowering medication before obesity-associated cancer diagnosis
- Incident obesity-associated cancer diagnosed after medication initiation
- No dispensing of the study drug class during the 6-month washout period before the first qualifying prescription
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chung Shan Medical University Hospital Coordinator of this site? Confirm its status | Taichung | Taiwan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.